SUPPLEMENTAL CONTENTS

Supplemental Table 1: Codes

Supplemental Data 1

Supplemental Table 2: Adverse outcomes among patients with nRVT in Ontario from 1992-2016 (after adding prematurity in the multivariate model)

Supplemental Figure 1: Cumulative risk of adverse outcomes following nRVT over 10 years of follow-up in subset that survives the first year following nRVT without outcome.

	ICD-9	ICD-10	OHIP
Neonatal renal vein thrombosis*	4533	1823	
Chronic kidney disease	2504, 4030, 4039, 4040, 4049, 40501, 40511, 40591, 4401, 44621, 581, 582, 583, 585, 586, 587, 5880, 5888, 5889, 589, 5900, 5937, 7910, 7944	A181, N290, E1020, E1021, E1120, E132, E142, M1039, I120, I129, I130, I131, I132, I139, I150, I701, M310, N03, N04, N05, N06, N07, N08, N11, N12, N137, N138, N139, N14, N15, N16, N180, N188, N189, N19, N250, N258, N259, N26, N27, R80, R944	403,581, 582,585, 586
Hypertension	401, 402, 403, 404, 405	110, 111, 112, 113, 115	401,402, 403
End-stage renal disease†	769	P22	769
Central venous catheterization‡	1IS53GRLF, 1IS53HNLF, 1IS54, 1IS54GRGX, 1IS54HAC1, 1IS54HAD2, 1IS54HAD3, 1IS54HALF, 1IS54JALF, 1IS55, 1IS55GRFK, 1IS55GRKA, 1IS55GRLF, 1IS55GRLG, 1IS55GRNR, 1IS55LAKA, 1IS55LALF, 1IS55LALG	9806, 5093, 1067, 5149, 5092	G282, S311
Congenital heart disease	745, 746, 747	Q20-Q28	745, 746, 747

Supplementary Table 1: Codes

Respiratory	769	P22	769	
distress				
syndrome				
Sepsis	0031, 0362, 0380, 0382,	A021, A392, A393, A394,	038	
	0383, 03840, 03841,	A400, A401, A402, A408,		
	03842, 03843, 03844,	A409-A412, A403, A414		
	03849, 0388, 0389			
NICU	SCU: 10,20, 25, 30, 40, 45, 50, 51, 52, 53, 60, 70, 80, 90, 93, 95			
admission§				
Maternal	648.0, 648.8	O24	250	
diabetes				
Pre-eclampsia	642.4, 642.5, 642.6,	010, 011, 014, 015, 016	642	
or eclampsia	642.7, 642.1, 642.3, 642.9			

*Diagnosis must occur between 0-28 days of age.

†Criteria for a diagnosis of ESKD included two ESKD codes for either chronic dialysis separated by a 90-day±14-day period or kidney transplant.

‡Coding by Canadian Classification of Procedures (corresponding to ICD-9 years) and Canadian Classification of Interventions (corresponding to ICD-10-CA years).

§NICU admission was recorded if one of the corresponding codes was reported ≤28 days of age.

Supplemental Data 1

The algorithm that we used to identify CKD was developed by Fleet et al. in 2013.²⁴ It consisted of 11 CKD codes and defined a patient as having CKD if one of these codes was recorded in a health-administrative database within a 5-year window. The sensitivity was 32.7% [95% confidence interval: (95% CI): 32.0 to 33.3%]. All specificities were over 94%. The positive and negative predictive values were 65.4% (95% CI: 64.4 to 66.3%) and 88.8% (95% CI: 88.6 to 89.0%), respectively.

For hypertension, we used an adult case-definition algorithm²⁶ employing 2 outpatient physician billing claims. This algorithm had a sensitivity of 73% (95% confidence interval [CI] 69%–77%), a specificity of 95% (CI 93%–96%), a positive predictive value of 87% (CI 84%–90%), and a negative predictive value of 88% (CI 86%–90%) for detecting hypertensive adults compared with physician-assigned diagnoses.

Long-term Outcomes	nRVT (n=85)	Comparator (n=3,010,525)	Measures	P-value
Composite outcome*, <i>n</i> (%)	49 (57.6%)	90,050 (3.0%)	Stdiff 1.48	
IR per 1000 person-years	111.8	2.56		
Unadjusted HR (95% CI)	42.3 (28.9-62.1)	Ref.		<0.0001
Adjusted† HR (95% CI) (without prematurity data)	15.5 (11.7-20.6)	Ref.		<0.0001
Number of patients with prematurity data (2002, onwards)	47	1,819,111		
Adjusted HR (95% CI), including prematurity (2002, onwards)	9.27 (6.16-14.0)	Ref.		<0.0001
CKD or Mortality, <i>n</i> (%)	39 (45.9%)	32,016 (1.1%)	Stdiff 1.25	
IR per 1000 person-years	66.5	0.9		
Unadjusted HR (95% CI)	67.5 (46.8-97.4)	Ref.		<0.0001
Adjusted HR (95% CI) (without prematurity data)	12.3 (8.9-16.8)	Ref.		<0.0001
Adjusted HR (95% CI), including prematurity (2002, onwards)	10.8 (6.87-17.0)	Ref.		<0.0001
Hypertension, <i>n</i> (%)	33 (38.8%)	64,458 (2.1%)	Stdiff 1.02	
IR per 1000 person-years	53.2	1.83		
Unadjusted HR (95% CI)	30.0 (19.8-45.5)	Ref.		<0.0001
Adjusted HR (95% CI) (without prematurity data)	15.7 (11.1-21.1)	Ref.		<0.0001
Adjusted HR (95% CI), including prematurity (2002, onwards)	7.28 (4.13-12.9)	Ref.		<0.0001

Supplemental Table 2: Adverse outcomes among patients with nRVT in Ontario from 1992-2016 (after adding prematurity in the multivariate model)

SUPPLEMENTAL FIGURE CAPTIONS:

Supplemental Figure 1: Cumulative risk of adverse outcomes following nRVT over 10 years of follow-up in subset that survives the first year following nRVT without outcome. In each figure, the red line represents the cumulative probability of adverse outcomes among patients with nRVT; the green line represents the risk among general neonatal population over time. (A) Cumulative risk of CKD, all-cause mortality or hypertension. (B) Cumulative risk of Hypertension. (C) Cumulative risk of CKD and/or all-cause mortality. nRVT, neonatal renal vein thrombosis; CKD, chronic kidney disease




Figure 1A

